Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline

目前的现金和现金等价物预计足以支持2024年第四季度的公司运营；评估为后期临床管道的未来发展提供资金的选项

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced a strategic reprioritization and cost reduction plan as the Company evaluates all financing options to support next steps across its late-stage clinical pipeline for ABP-450 that targets multiple indications.

加利福尼亚州欧文市，2024年5月29日（环球通讯社）--永旺生物制药公司（“永旺”或“公司”）（纽约证券交易所：永旺），一家临床阶段的生物制药公司，专注于开发一种专有的肉毒杆菌毒素复合物，用于治疗多种衰弱的医疗状况，宣布了一项战略性的优先权调整和成本降低计划，该公司评估了所有融资方案，以支持针对多种适应症的ABP-450晚期临床管道的下一步。

The Company’s actions are expected to be sufficient to extend its cash runway into the fourth quarter of 2024..

预计该公司的行动足以将其现金周转期延长至2024年第四季度。。

“Following a strategic review of our resources, we made the decision to implement several cost reductions that will preserve cash while still supporting corporate activities. Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs.

“在对我们的资源进行战略审查后，我们决定实施几项成本削减措施，以节省现金，同时仍支持企业活动。在获得额外资金后，我们将宣布修订后的ABP-450计划临床开发战略。

We look forward to keeping shareholders apprised of our progress,” commented Marc Forth, AEON’s president and chief executive officer..

我们期待着让股东了解我们的进展，”永旺总裁兼首席执行官马克·福思评论道。。

As part of the cash preservation strategy, AEON has reduced its workforce by approximately 55%. This includes the Company’s termination of Peter Reynolds as the chief financial officer, principal financial officer and principal accounting officer, effective as of May 17, 2024. Concurrently, the Board appointed Mr.

作为现金保存战略的一部分，永旺减少了约55%的员工。这包括公司终止Peter Reynolds作为首席财务官、首席财务官和首席会计官的职务，自2024年5月17日起生效。同时，董事会任命了。

Forth as principal financial officer and Jennifer Sy, the Company’s corporate controller, as principal accounting officer, each effective as of May 17, 2024. Mr. Forth and Ms. Sy will continue in their prior roles. These cost reduction actions will also include efforts to reduce additional operating costs and are expected to be substantially completed by June 2024..

福思担任首席财务官，詹妮弗·西（JenniferSy）担任公司的公司控制官，担任首席会计官，自2024年5月17日起生效。福思先生和西女士将继续担任之前的职务。这些降低成本的行动还将包括努力降低额外的运营成本，预计将于2024年6月基本完成。。

“We are grateful for Peter’s contributions to the Company and wish him success in his future endeavors. Peter effectively guided AEON’s finance and accounting functions through multiple important milestones, including our business combination that resulted in AEON being publicly listed,” stated Mr. Forth..

福思先生表示：“我们感谢彼得对公司的贡献，并祝他在未来的努力中取得成功。彼得通过多个重要里程碑有效地指导了永旺的财务和会计职能，包括我们的企业合并，导致永旺上市。”。。

In addition, subsequent to evaluating the topline interim analysis, which did not achieve its primary or secondary endpoints, the Company has discontinued the Phase 2 study of ABP-450 for the prevention of chronic migraine, which had previously completed enrollment and dosing of patients, and ceased enrollment and dosing of patients in the Company’s migraine open label extension study (the “OLE Study”).

此外，在评估未达到主要或次要终点的topline中期分析后，该公司停止了ABP-450预防慢性偏头痛的第二阶段研究，该研究先前已完成患者的登记和给药，并停止了该公司偏头痛开放标签扩展研究（“OLE研究”）中患者的登记和给药。

Patients in both studies will be monitored for safety purposes through the 12-week period following their last treatment. The Company will continue its analysis of interim data from the study..

两项研究中的患者将在最后一次治疗后的12周内进行安全监测。该公司将继续分析该研究的中期数据。。

About AEON Biopharma

关于永旺生物制药

AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau.

永旺是一家临床阶段的生物制药公司，专注于开发其专有的肉毒杆菌毒素复合物ABP-450（prabotulinumtoxinA）注射液或ABP-450，用于使人衰弱的医疗条件，最初专注于神经科学市场。ABP-450是目前由Evolus以Jeuveau的名称批准和销售用于化妆品适应症的同一种肉毒杆菌毒素复合物。

ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.

ABP-450由大宇根据现行良好生产规范（cGMP）在美国食品和药物管理局、加拿大卫生部和欧洲药品管理局批准的设施中生产。永旺在美国、加拿大、欧盟、英国和某些其他国际领土拥有ABP-450治疗适应症的独家开发和分销权。

The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com..

该公司建立了一支经验丰富的管理团队，在生物制药和肉毒杆菌毒素的开发和商业化方面具有丰富的经验。要了解有关永旺的更多信息，请访问www.aeonbiopharma.com。。

Forward-Looking Statements

前瞻性声明

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance. For example, statements regarding the closing of each installment of the Private Placement, AEON’s expected capital resources and liquidity needs and the anticipated timing of AEON’s clinical results are forward-looking statements.

本新闻稿中的某些声明可能被视为前瞻性声明。前瞻性报表通常与未来事件或永旺未来的财务或经营业绩有关。例如，关于私募每期的结束、永旺的预期资本资源和流动性需求以及永旺临床结果的预期时间的声明都是前瞻性声明。

In some cases, you can identify forward-looking statements by terminology such as 'plan', 'possible', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements..

在某些情况下，您可以通过术语来识别前瞻性陈述，例如“计划”、“可能”、“预测”、“预期”、“打算”、“意志”、“估计”、“预期”、“相信”、“预测”、“潜在”或“继续”，或这些术语的否定或其变体或类似术语。此类前瞻性声明受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与此类前瞻性声明明示或暗示的结果存在重大差异。。

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON’s future capital requirements, including with respect to potential obligations pursuant to the forward purchase agreements; (iii) AEON’s ability to raise financing in the future; (iv) AEON’s ability to continue to meet continued stock exchange listing standards; (v) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; and (vi) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the 'SEC'), which are available on the SEC’s website at www.sec.gov..

这些前瞻性陈述基于估计和假设，虽然永旺及其管理层认为这些估计和假设是合理的，但本质上是不确定的。可能导致实际结果与当前预期存在重大差异的因素包括但不限于：（i）可能对永旺或其他人提起的任何法律诉讼的结果；（ii）永旺未来的资本要求，包括根据远期购买协议的潜在义务；（iii）永旺未来融资的能力；（iv）永旺继续满足证券交易所持续上市标准的能力；（v） 永旺可能受到其他经济、商业、监管和/或竞争因素的不利影响；（vi）公司向美国证券交易委员会（“SEC”）提交的文件中题为“风险因素”和“关于前瞻性陈述的警示说明”的章节中规定的其他风险和不确定性，可在SEC网站www.SEC.gov上查阅。。

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

本新闻稿中的任何内容均不应被视为任何人表示将实现本文所述的前瞻性声明，或表示将实现此类前瞻性声明的任何预期结果。您不应过度依赖前瞻性陈述，因为前瞻性陈述仅在做出之日起生效。

AEON does not undertake any duty to update these forward-looking statements..

永旺不承担更新这些前瞻性声明的任何责任。。

Contacts

联系人

Investor Contact:

投资者联系人：

Corey Davis, Ph.D.

科里·戴维斯博士。

LifeSci Advisors

LifeSci顾问

+1 212 915 2577

+1 212 915 2577

cdavis@lifesciadvisors.com

cdavis@lifesciadvisors.com

Source: AEON Biopharma

来源：AEON生物制药